Chromosome Transplantation: Correction of the Chronic Granulomatous Disease Defect in Mouse Induced Pluripotent Stem Cells.
Aminopterin
/ metabolism
Animals
Base Sequence
CRISPR-Cas Systems
Cell Differentiation
Chromosomes, Mammalian
Clone Cells
Culture Media
/ chemistry
Disease Models, Animal
Gene Editing
/ methods
Genetic Therapy
/ methods
Granulocytes
/ cytology
Granulomatous Disease, Chronic
/ genetics
Humans
Hypoxanthine
/ metabolism
Hypoxanthine Phosphoribosyltransferase
/ deficiency
Induced Pluripotent Stem Cells
/ drug effects
Male
Mice
NADPH Oxidase 2
/ deficiency
Proof of Concept Study
Sequence Deletion
Thioguanine
/ metabolism
Thymidine
/ metabolism
X Chromosome
/ chemistry
CRISPR/Cas system
Chronic granulomatous disease
Genetic therapy
Induced pluripotent stem cells
X-linked combined immunodeficiency diseases
Journal
Stem cells (Dayton, Ohio)
ISSN: 1549-4918
Titre abrégé: Stem Cells
Pays: England
ID NLM: 9304532
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
01
08
2018
revised:
12
02
2019
accepted:
12
03
2019
pubmed:
22
3
2019
medline:
27
6
2020
entrez:
22
3
2019
Statut:
ppublish
Résumé
In spite of the progress in gene editing achieved in recent years, a subset of genetic diseases involving structural chromosome abnormalities, including aneuploidies, large deletions and complex rearrangements, cannot be treated with conventional gene therapy approaches. We have previously devised a strategy, dubbed chromosome transplantation (CT), to replace an endogenous mutated chromosome with an exogenous normal one. To establish a proof of principle for our approach, we chose as disease model the chronic granulomatous disease (CGD), an X-linked severe immunodeficiency due to abnormalities in CYBB (GP91) gene, including large genomic deletions. We corrected the gene defect by CT in induced pluripotent stem cells (iPSCs) from a CGD male mouse model. The Hprt gene of the endogenous X chromosome was inactivated by CRISPR/Cas9 technology thus allowing the exploitation of the hypoxanthine-aminopterin-thymidine selection system to introduce a normal donor X chromosome by microcell-mediated chromosome transfer. X-transplanted clones were obtained, and diploid XY clones which spontaneously lost the endogenous X chromosome were isolated. These cells were differentiated toward the myeloid lineage, and functional granulocytes producing GP91 protein were obtained. We propose the CT approach to correct iPSCs from patients affected by other X-linked diseases with large deletions, whose treatment is still unsatisfactory. Stem Cells 2019;37:876-887.
Substances chimiques
Culture Media
0
Hypoxanthine
2TN51YD919
Cybb protein, mouse
EC 1.6.3.-
NADPH Oxidase 2
EC 1.6.3.-
Hypoxanthine Phosphoribosyltransferase
EC 2.4.2.8
Thioguanine
FTK8U1GZNX
Aminopterin
JYB41CTM2Q
Thymidine
VC2W18DGKR
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
876-887Informations de copyright
©AlphaMed Press 2019.